Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Clinical relevance of symptomatic superficial-vein thrombosis extension: lessons from the CALISTO study

Alain Leizorovicz, François Becker, Andrea Buchmüller, Isabelle Quéré, Paolo Prandoni, Hervé Decousus

Blood (2013) 122 (10): 1724–1729.

https://doi.org/10.1182/blood-2013-04-498014

Published: 2013

Includes: Supplemental data

Journal Articles

Fondaparinux Reduces All Types of Symptomatic Thromboembolic Complications in Patients with Superficial-Vein Thrombosis in the Legs: Data From the CALISTO Study

Alain Leizorovicz, MD, Paolo Prandoni, Hervé Décousus, MD

Blood (2011) 118 (21): 2310.

https://doi.org/10.1182/blood.V118.21.2310.2310

Published: 2011

Journal Articles

The risk of subsequent cancer and arterial cardiovascular events in patients with superficial vein thrombosis in the legs

Paolo Prandoni, Edoardo Casiglia, Valerie Tikhonoff, Alain Leizorovicz, Hervé Decousus, on behalf of the Calisto Investigators

Blood (2011) 118 (17): 4719–4722.

https://doi.org/10.1182/blood-2011-06-364232

Published: 2011

Journal Articles

Fondaparinux 2.5mg for the Treatment of Symptomatic, Isolated Superficial Vein Thrombosis (SVT): Preliminary Data From the Randomized Placebo-Controlled CALISTO Trial (on Behalf of the CALISTO Investigators).

Hervé Décousus, MD, Paolo Prandoni, MD, Alain Leizorovicz, MD

Blood (2009) 114 (22): 171.

https://doi.org/10.1182/blood.V114.22.171.171

Published: 2009

Journal Articles

No Accumulation of Peak Anti-Xa Activity of Tinzaparin in Elderly Patients with Moderate to Severe Renal Impairment: A Substudy of IRIS Clinical Trial.

Virginie Siguret, Alain Leizorovicz, MD, Eric Pautas, Isabelle Gouin-Thibault

Blood (2009) 114 (22): 172.

https://doi.org/10.1182/blood.V114.22.172.172

Published: 2009

Journal Articles

Tinzaparin Compared to Unfractionated Heparin for Initial Treatment of Deep Vein Thrombosis in Very Elderly Patients with Renal Insufficiency-the IRIS Trial

Alain Leizorovicz, MD

Blood (2008) 112 (11): 434.

https://doi.org/10.1182/blood.V112.11.434.434

Published: 2008

NARROW

Clinical relevance of symptomatic superficial-vein thrombosis extension: lessons from the CALISTO study

Fondaparinux Reduces All Types of Symptomatic Thromboembolic Complications in Patients with Superficial-Vein Thrombosis in the Legs: Data From the CALISTO Study

The risk of subsequent cancer and arterial cardiovascular events in patients with superficial vein thrombosis in the legs

Fondaparinux 2.5mg for the Treatment of Symptomatic, Isolated Superficial Vein Thrombosis (SVT): Preliminary Data From the Randomized Placebo-Controlled CALISTO Trial (on Behalf of the CALISTO Investigators).

No Accumulation of Peak Anti-Xa Activity of Tinzaparin in Elderly Patients with Moderate to Severe Renal Impairment: A Substudy of IRIS Clinical Trial.

Tinzaparin Compared to Unfractionated Heparin for Initial Treatment of Deep Vein Thrombosis in Very Elderly Patients with Renal Insufficiency-the IRIS Trial

Email alerts

ASH Publications

American Society of Hematology

Clinical relevance of symptomatic superficial-vein thrombosis extension: lessons from the CALISTO study

Fondaparinux Reduces All Types of Symptomatic Thromboembolic Complications in Patients with Superficial-Vein Thrombosis in the Legs: Data From the CALISTO Study

The risk of subsequent cancer and arterial cardiovascular events in patients with superficial vein thrombosis in the legs

Fondaparinux 2.5mg for the Treatment of Symptomatic, Isolated Superficial Vein Thrombosis (SVT): Preliminary Data From the Randomized Placebo-Controlled CALISTO Trial (on Behalf of the CALISTO Investigators).

No Accumulation of Peak Anti-Xa Activity of Tinzaparin in Elderly Patients with Moderate to Severe Renal Impairment: A Substudy of IRIS Clinical Trial.

Tinzaparin Compared to Unfractionated Heparin for Initial Treatment of Deep Vein Thrombosis in Very Elderly Patients with Renal Insufficiency-the IRIS Trial

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only